Clinical pharmacological test of calcium alginate capsules. -Optimization study of postprandial serum triglyceride elevation suppression effect (preliminary study)
Not Applicable
- Conditions
- Healthy subjects
- Registration Number
- JPRN-UMIN000050420
- Lead Sponsor
- Takasaki University of Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are taking dyslipidemia drugs. (Persons receiving treatment for hyperlipidemia) If the participant has some kind of disease and is under medication, and the cooperating doctor deems the participant unsuitable as a subject. Subjects who may have allergic symptoms to rubber or latex. Subjects who may have allergic symptoms to corn oil. If any of the results of HIV antigen/antibody, HBV, HCV, and syphilis tests at screening are positive. Subjects with obvious abnormalities in hematological and biochemical tests. Those who are pregnant, those who wish to become pregnant during the test, and those who are breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The maximum concentration (Cmax) of the postprandial serum triglyceride. The area under the curve (AUC) of the postprandial serum triglyceride. The serum triglyceride level (before, 30, 60, 90, 120, 240 and 360 minutes after the fat food load).
- Secondary Outcome Measures
Name Time Method